Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.13 Consensus Target Price from Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have received an average rating of “Buy” from the ten research firms that are covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $9.13.

A number of brokerages have weighed in on TRVI. D. Boral Capital reissued a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, December 4th. HC Wainwright reaffirmed a “buy” rating on shares of Trevi Therapeutics in a research report on Wednesday, December 4th. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Leerink Partnrs raised Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Leerink Partners initiated coverage on Trevi Therapeutics in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price on the stock.

Trevi Therapeutics Stock Up 0.8 %

Shares of Trevi Therapeutics stock opened at $2.68 on Friday. Trevi Therapeutics has a fifty-two week low of $1.10 and a fifty-two week high of $4.00. The firm has a market cap of $206.00 million, a PE ratio of -6.09 and a beta of 0.96. The business’s fifty day moving average is $2.98 and its two-hundred day moving average is $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the prior year, the firm earned ($0.08) earnings per share. Equities research analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Trading of Trevi Therapeutics

Large investors have recently modified their holdings of the business. Logos Global Management LP grew its stake in shares of Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after acquiring an additional 600,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Trevi Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after acquiring an additional 60,249 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Trevi Therapeutics by 38.8% during the second quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock valued at $532,000 after acquiring an additional 49,884 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Trevi Therapeutics during the first quarter valued at about $47,000. Finally, Ally Bridge Group NY LLC acquired a new stake in shares of Trevi Therapeutics during the second quarter valued at about $4,395,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.